Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 6 |
| List of Tables | 6 | 1 |
| List of Figures | 7 | 1 |
| Introduction | 8 | 1 |
| Global Markets Direct Report Coverage | 8 | 1 |
| Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) Overview | 9 | 1 |
| Therapeutics Development | 10 | 4 |
| Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) Products under Development by Stage of Development | 10 | 1 |
| Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) Products under Development by Therapy Area | 11 | 1 |
| Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) Products under Development by Indication | 12 | 2 |
| Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) Pipeline Products Glance | 14 | 3 |
| Late Stage Products | 14 | 1 |
| Early Stage Products | 15 | 1 |
| Unknown Stage Products | 16 | 1 |
| Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) Products under Development by Companies | 17 | 5 |
| Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) Products under Development by Universities/Institutes | 22 | 2 |
| Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) Therapeutics Assessment | 24 | 5 |
| Assessment by Monotherapy/Combination Products | 24 | 1 |
| Assessment by Mechanism of Action | 25 | 1 |
| Assessment by Route of Administration | 26 | 2 |
| Assessment by Molecule Type | 28 | 1 |
| Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) Companies Involved in Therapeutics Development | 29 | 14 |
| Aptose Biosciences Inc. | 29 | 1 |
| Arvinas, Inc. | 30 | 1 |
| C4 Therapeutics, Inc. | 31 | 1 |
| Constellation Pharmaceuticals, Inc. | 32 | 1 |
| ConverGene, LLC | 33 | 1 |
| Daiichi Sankyo Company, Limited | 34 | 1 |
| Dybly AG | 35 | 1 |
| F. Hoffmann-La Roche Ltd. | 36 | 1 |
| Incyte Corporation | 37 | 1 |
| Kainos Medicine, Inc. | 38 | 1 |
| Merck &Co., Inc. | 39 | 1 |
| Resverlogix Corp. | 40 | 1 |
| Trillium Therapeutics Inc. | 41 | 1 |
| Zenith Epigenetics Corp | 42 | 1 |
| Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) Drug Profiles | 43 | 36 |
| apabetalone Drug Profile | 43 | 9 |
| ARV-763 Drug Profile | 52 | 1 |
| ARV-771 Drug Profile | 53 | 1 |
| ARV-825 Drug Profile | 54 | 1 |
| birabresib Drug Profile | 55 | 2 |
| CK-103 Drug Profile | 57 | 1 |
| CPI-0610 Drug Profile | 58 | 1 |
| CVG-101 Drug Profile | 59 | 1 |
| DYB-186 Drug Profile | 60 | 1 |
| INCB-54329 Drug Profile | 61 | 1 |
| KM-601 Drug Profile | 62 | 1 |
| MA-2014 Drug Profile | 63 | 1 |
| MS-417 Drug Profile | 64 | 1 |
| NEO-2734 Drug Profile | 65 | 1 |
| PLX-51107 Drug Profile | 66 | 1 |
| RG-6146 Drug Profile | 67 | 1 |
| S-10 Drug Profile | 68 | 1 |
| SF-2535 Drug Profile | 69 | 1 |
| Small Molecules to Inhibit BRD4 and HDAC1 for Oncology Drug Profile | 70 | 1 |
| Small Molecules to Inhibit BRD4 for Malignant Peripheral Nerve Sheath Tumors Drug Profile | 71 | 1 |
| Small Molecules to Inhibit BRD4 for Oncology Drug Profile | 72 | 1 |
| Small Molecules to Target BRD4 and VHL for Lung Cancer Drug Profile | 73 | 1 |
| Small Molecules to Target BRD4 and VHL for Ovarian Cancer Drug Profile | 74 | 1 |
| SRX-2523 Drug Profile | 75 | 1 |
| TTI-281 Drug Profile | 76 | 1 |
| ZEN-3365 Drug Profile | 77 | 1 |
| ZEN-3694 Drug Profile | 78 | 1 |
| Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) Dormant Projects | 79 | 1 |
| Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) Featured News &Press Releases | 80 | 9 |
| Aug 04, 2016: The Life Sciences Report Examines Resverlogix New Trial | 80 | 1 |
| Jul 21, 2016: Resverlogix Announces Dosing of First Two Patients in Expanded Renal and Orphan Programs | 80 | 1 |
| Jun 15, 2016: Zenith Announces Dosing of First Patient in Phase 1 Clinical Trial and Corporate Update Webcast Details | 81 | 1 |
| Jun 02, 2016: Resverlogix Announces Lead Drug Apabetalone Publication and Presentation at BIO International 2016 | 81 | 1 |
| May 24, 2016: Resverlogix Presents New Complement Data and Establishes Renal Clinical Advisory Board at the 53rd Annual European Renal Association - European Dialysis &Transplant Association Congress (ERA-EDTA) | 82 | 1 |
| Jan 25, 2016: Resverlogix Manuscript on BET-inhibitor apabetalone (RVX-208) Accepted into the Atherosclerosis Journal | 83 | 1 |
| Nov 11, 2015: Resverlogix Commences Dosing in Phase 3 Clinical Trial BETonMACE | 83 | 1 |
| Nov 09, 2015: Resverlogix Presents Important New Data at the Annual American Society of Nephrology Kidney Week Conference | 83 | 1 |
| Oct 26, 2015: Resverlogix Commences Phase 3 Clinical Trial BETonMACE With Apabetalone | 84 | 1 |
| Sep 29, 2015: Resverlogix Provides Research and Development Update in New York City | 84 | 1 |
| Sep 24, 2015: Resverlogix Announces the commencement of an Orphan Disease Program specific for Complement Mediated Diseases | 85 | 1 |
| Aug 31, 2015: Resverlogix Presents New Data at the European Society of Cardiology Congress 2015 on RVX-208 'apabetalone' a Selective BET Inhibitor | 85 | 1 |
| Aug 04, 2015: International Clinical Steering Committee Announced for Resverlogix's Phase 3 BETonMACE Clinical Trial with RVX-208 "apabetalone" | 86 | 1 |
| Jun 22, 2015: Resverlogix Officially Attains Phase 3 Status with a European Regulatory Authority | 87 | 1 |
| Jun 08, 2015: Resverlogix Reports on the Beneficial Effects of RVX-208 on Glucose Metabolism in Prediabetes Mellitus at the American Diabetes Association's (ADA) Scientific Sessions in Boston, MA | 88 | 1 |
| Appendix | 89 | 2 |
| Methodology | 89 | 1 |
| Coverage | 89 | 1 |
| Secondary Research | 89 | 1 |
| Primary Research | 89 | 1 |
| Expert Panel Validation | 89 | 1 |
| Contact Us | 89 | 1 |
| Disclaimer | 90 | 1 |
